Compare AbbVie Inc (ABBV) vs iShares 3 7 Year Treasury Bond ETF (IEI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs iShares 3 7 Year Treasury Bond ETF — how do they compare? AbbVie Inc trades at $249.85 (market cap $441.94B), while iShares 3 7 Year Treasury Bond ETF trades at $116.57. The key difference: AbbVie Inc pays a 2.77% dividend while iShares 3 7 Year Treasury Bond ETF pays none, and AbbVie Inc is trading nearer its 52-week high, iShares 3 7 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| ABBV | IEI | |
|---|---|---|
Market Cap | $441.94B | — |
Sector | Health | Fixed Income |
52-Week High | $263.58 | $120.72 |
52-Week Low | $197.38 | $116.16 |
Enterprise Value | $506.19B | — |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $247.91, up 0.76% today, with a bullish technical signal and strong analyst support. Recent earnings beats and a 70.73% buy consensus highlight robust fundamentals, driven by Skyrizi and Rinvoq growth offsetting Humira declines. Positive news includes Phase 2 ovarian cancer data and institutional stake increases, reinforcing momentum.
Outlook remains positive with a $278.69 price target, though risks include patent cliffs and debt levels. Revenue growth and dividend stability offer appeal, but investors should monitor competitive pressures and regulatory developments for sustained performance.
IEI, the iShares 3-7 Year Treasury Bond ETF, trades at $116.565, up 0.27% today, with technical indicators showing a bearish trend from moving averages and neutral oscillators. Recent news highlights institutional activity, including Bank of America increasing its stake by 39.7% in the latest quarter (Defense World, 2026-08-01). The fund maintains a conservative profile with regular dividend distributions, appealing to income-focused investors amid volatile bond markets.
The outlook for IEI is cautious due to rising Treasury yields and inflation concerns, posing risks from potential Fed rate hikes. However, its government backing and lower volatility offer stability for risk-averse portfolios, with income generation from dividends remaining a key attraction despite macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About iShares 3 7 Year Treasury Bond ETF
IEI tracks the ICE U.S. Treasury 3-7 Year Bond Index, offering exposure to intermediate-term government debt. It serves as a conservative middle ground in the Treasury yield curve, providing higher yields than short-term bills with less volatility than long-term bonds.
Read more on IEI →
